The findings provide further support of recommendations in the clinical guidelines to favor one therapy over the other. Patients with chronic obstructive pulmonary disease (COPD) being treated with ...
Please provide your email address to receive an email when new articles are posted on . Inhalers with a long-acting muscarinic antagonist and a long-acting beta agonist (LABA) resulted in “better ...
RIDGEFIELD, Conn. and NORWALK, Conn., Nov. 17, 2022 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals Inc. welcomes the updated 2023 Global Initiative for Chronic Obstructive Lung Disease (GOLD) ...
LAMAs were found to be safe and effective in the treatment of COPD and have been recommended by international clinical guidelines for the management of symptoms in COPD. A population-based cohort ...
Please provide your email address to receive an email when new articles are posted on . Perioperative combination therapy using a long-acting muscarinic antagonist and long-acting beta agonist may be ...
Triple therapy in COPD significantly improves lung function vs LAMA monotherapy, LABA/LAMA, and ICS/LABA, although evidence showing this is often low quality. Triple therapy is likely effective, safe, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results